Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions
Shock, CardiogenicExtra-Corporeal-Life-Support ( ECLS)Autonomic Nervous System DiseasesInflammation
Interventions
DIAGNOSTIC_TEST

Biological

"We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~1. Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~2. Lymphocytes Th1/Th2 pattern by flow cytometry~3. Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~1. Hemodynamic parameters~2. Cumulated doses of catecholamines~3. Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)"

Trial Locations (1)

54000

CHRU Nancy, Nancy

All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

Central Hospital, Nancy, France

OTHER

NCT03327493 - Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO | Biotech Hunter | Biotech Hunter